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Abstract
Alzheimer’s disease (AD) has become one of the most threatening diseases in 
the elderly, and type 2 diabetes mellitus (T2DM) is a major health problem in the 
world, representing 7.4% of the population. Several studies have produced epi-
demiological, clinical, and pathological evidence of the relationship between AD 
and T2DM. Laboratory research using animal models has identified mechanisms 
shared by both T2DM and AD. Particularly, there is an increase of tau phosphoryla-
tion and cleavage, which is known to be particularly toxic to neurons and to form 
a nucleation for neurofibrillary tangles. Also, alterations in synaptic plasticity are 
associated to tau pathology through the direct abnormal interaction of pathological 
tau with synaptic proteins and indirectly through Tau-activated neuroinflammatory 
processes. Many T2DM complications are potentiated or initiated by the accu-
mulation of specific forms of advanced glycation end products (AGEs) and their 
interaction with its receptors (RAGE). AGEs promote β-amyloid aggregation and 
cytotoxicity, while glycation of tau may enhance their aggregation. Therefore, this 
review addresses the analysis of the common mechanisms where the major molecu-
lar players of these two diseases participate and contribute to a better understand-
ing of these diseases in their pathogenic relationship.
Keywords: Alzheimer’s disease, type 2 diabetes mellitus, metabolic syndrome, 
β-Amyloid, tau
1. Introduction
Demographic trends show a dramatic increase in the elderly population; unfor-
tunately this group showed a higher prevalence of chronic diseases worldwide, 
becoming a serious public health problem in both developed and developing 
countries [1, 2]. The increasing aging population phenomenon in association with 
chronic diseases has several repercussions: economic, social, and medical. Among 
these chronic diseases, the most prominent for occupying the first places in epi-
demiological studies are: cardiovascular, cerebrovascular, diabetes, cancer, and 
dementias [2, 3].
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Diabetes mellitus (DM) is a complex and heterogeneous group characterized by 
hyperglycemia. In 2015, there were 415 million people with diabetes worldwide and 
this number is expected to increase to 642 million by 2040 [4, 5]. The major risk 
factors in DM are eating a diet high in fats and simple sugars coupled with seden-
tary lifestyle [3]. On the other hand, Alzheimer’s disease (AD) is the most common 
dementia worldwide [6].
Several studies have produced epidemiological, clinical, and pathological 
evidence of the relationship between AD and DM [7, 8]. It has been reported that 
patients with diabetes have a 50–75% increased risk of developing AD compared 
with age- and gender-matched patients without diabetes [9]. In fact, both entities 
share metabolic dysfunctions associated with different pathological develop-
ments [10].
DM is a chronic disease characterized by the absolute or relative shortage of 
insulin, leading to chronic hyperglycemia, which results either in the progressive 
failure of pancreatic β-cell function and consequently a lack of insulin production 
(type 1 diabetes, T1DM) or in the development of insulin resistance and subse-
quently the loss in β-cell function (type 2 diabetes, T2DM) [4, 11]. Examination 
of diagnoses reveals that AD is by far the most common cause of dementia among 
people with T2DM (e.g., 91%) [12]; the insulin resistance in this metabolic disease is 
not yet clear, but obesity and age are the major risk factors [13, 14].
AD is the most common dementing disorder of late life, characterized by 
progressive loss of cholinergic neurons and a devastating cognitive decline [10]. 
The two major histopathological features of AD are: (1) amyloid plaques and (2) 
neurofibrillary tangles (NFTs). Amyloid plaques are composed of β-amyloid (Aβ) 
peptide, produced by the proteolytic cleavage of the amyloid precursor protein 
(APP) [9]. On the other hand, truncated and phosphorylated tau protein is the main 
component in the NFT and the amount of these aggregates correlates with cognitive 
impairment [15]. In AD, abnormal tau aggregates are present in the cell body and 
proximal dendrites [16].
Research studies, using animal models have identified mechanisms that are 
shared by T2DM and AD [7]. AD pathology has been evaluated extensively in two 
widely available T2DM spontaneous models: Bio-Breeding Zucker diabetic rat/Wor 
rats and db/db mice. They observed an increase in tau phosphorylation and cleav-
age, which is known to be particularly toxic to neurons and forms the nucleation for 
NFT [9]. The hyperglycemia in T2DM induces an increase in advanced glycation 
end products (AGEs), and these molecules also accumulate with aging and demen-
tia [17, 18]. AGEs promote Aβ aggregation and cytotoxicity [19], while glycation of 
tau promotes their aggregation [20].
A fat and simple sugars-rich diet, coupled with sedentary lifestyle, is also a 
strong risk factor associated with another disorder known as metabolic syndrome 
(MS), characterized by abdominal obesity, dyslipidemias, high blood pressure, 
hyperglycemia, insulin resistance, and high body mass index [21–23]. Since many 
of the characteristic features of MS, including insulin resistance, obesity, dyslipid-
emia, and high blood pressure, are risk factors not only for DM and cardiovascular 
disease but also for AD [24], this review will focus on the common mechanisms 
involved in the development of these diseases.
2. Metabolic syndrome
Metabolic syndrome is a complex disorder defined by a cluster of interconnected 
factors that increase the risk of cardiovascular atherosclerotic diseases and T2DM 
[25]. MS is also associated with various cardiometabolic risk factors modulated by 
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several environmental conditions, mainly an inadequate diet and physical inactivity 
[26]. The syndrome presents simultaneously with insulin resistance, alterations in 
blood glucose levels, hypertension, triglycerides above normal, levels below recom-
mended of high density lipoprotein (cHDL), and visceral obesity [22]. The process 
starts with an inadequate diet as well as a sedentary life, which induce the develop-
ment of obesity, usually with episodes of hyperinsulinemia, which in turn can 
produce insulin resistance due to the blockade of insulin receptors and glucose trans-
porters, with the presence of high levels of fatty acids and glucose in the extracellu-
lar space (associated with DM), associated with hypertension and low synthesis and 
increased triglyceride catabolism. There are also dyslipidemias due to the inability to 
inhibit lipolysis in fatty tissues, with an increase in low-density lipoprotein (cLDL) 
and a decrease in cHDL. Finally, obesity develops due to the continuous increase in 
visceral fat, a permanent pro-inflammatory state, and endothelial dysfunction [27].
2.1 Etiology
The etiology of MS is attributed to the combination of genetic and environmen-
tal factors associated with lifestyles.
Obesity is “a chronic, relapsing, multifactorial, neurobehavioral disease, 
wherein an increase in body fat promotes adipose tissue dysfunction and abnormal 
fat mass physical forces, resulting in adverse metabolic, biomechanical, and psy-
chosocial health consequences.” Includes the increase and accumulation of fat at 
the visceral level (fatty tissue deposit mainly in the liver, intestine and pancreas), 
the tissue is rich in macrophages; adipocytes produce a variety of biologically active 
molecules, known together as adipokines [28].
Dyslipidemia is a disorder of lipoprotein metabolism, including lipoprotein 
overproduction or deficiency. Dyslipidemias may be manifested by elevation of 
the total cholesterol, the “bad” cLDL cholesterol and the triglyceride concentra-
tions, and a decrease in the “good” cHDL cholesterol concentration in the blood. 
Dyslipidemia has been attributed to the inability of insulin to inhibit lipolysis at the 
level of adipose tissue, which leads to an increase in the release of free fatty acids 
and a greater contribution of these to the liver, inducing increased apolipoprotein B 
secretion [29].
Hypertension, also known as high or raised blood pressure, is a condition in 
which the blood vessels have persistently raised pressure. Hypertension is produced 
as a consequence of the effects of the hyperinsulinemia. The blood pressure rises, 
due to an increase in the reabsorption of sodium and water in the renal proximal 
tubule. Hyperinsulinemia also increases peripheral vascular resistance and increases 
the activation of the sympathetic system with the consequent increase in circulating 
catecholamines and stimulation of the renin angiotensin-aldosterone system [30].
Hyperglycemia is the technical term for high blood glucose blood sugar. High 
blood sugar happens when the body has too little insulin or when the body cannot 
use insulin properly. This poor insulin secretion or action is due to lipotoxicity of 
the pancreatic β cells, since the excessive accumulation of triglycerides in pancre-
atic islets increases the expression of the inducible nitric oxide synthase (iNOS) 
enzyme, increasing nitric oxide levels and producing impaired function and finally 
apoptosis. The β cells, progressively losing its ability to compensate the insulin resis-
tance with more insulin secretion, and finally increasing blood glucose levels [31].
Insulin resistance is defined clinically as the inability of a known quantity of 
exogenous or endogenous insulin to increase glucose uptake and utilization in an 
individual as much as it does in a normal population. Insulin action is the conse-
quence of insulin binding to its plasma membrane receptor and the signal is trans-
mitted through the cell by a series of protein–protein interactions. Classically, this 
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refers to impaired sensitivity to insulin-mediated glucose disposal. Compensatory 
hyperinsulinemia occurs when pancreatic β cell secretion increases to maintain 
normal blood glucose levels in the setting of peripheral insulin resistance in muscle 
and adipose tissue [32].
Pro-inflammatory states acute and chronic hyperglycemias are pro-inflam-
matory states, central obesity and insulin resistance being implicated in its etiol-
ogy. Adipose tissue is biologically active as an endocrine and paracrine organ. 
Adipocytes undergo hypertrophy and hyperplasia in response to nutritional excess 
that can lead the cells to outgrow their blood supply with induction of a hypoxic 
state. Hypoxia can lead to cell necrosis with macrophage infiltration and the 
production of adipokines, which include the pro-inflammatory mediators interleu-
kin-6 (IL-6) and tumor necrosis factor alpha (TNF-α), as well as the prothrombotic 
mediator plasminogen activator inhibitor-1 (PAI-1, [33]). These mediators induce 
an oxidative stress and endothelial dysfunction, and nitric oxide (NO) regulates 
the vascular tone by activating guanylate cyclase and increasing the 3′5′-guanosine 
monophosphate and inhibits platelet activity. When there is an excessive produc-
tion of superoxide anion, the bioavailability of NO decreases due to their oxidative 
inactivation in the vascular wall [34].
2.2 Diagnosis of metabolic syndrome
The diagnostic criteria of the MS have been subject to many definitions, such 
as those of World Health Organization (WHO), Adult Treatment Panel III of 
the National Cholesterol Education Program (ATP III), International Diabetes 
Federation (IDF), American Heart Association (AHA) and others. However, a new 
global definition of the metabolic syndrome was proposed by the IDF where obesity 
represents a necessary requirement for the diagnosis of MS. Once the obesity is con-
firmed, the diagnosis continues with the presence of two or more parameters such 
as decrease in cHDL and increase in triglyceride, blood pressure and blood glucose 
[35–37]. However, even with a good diagnosis for MS, in most cases the treatment is 
inadequate [38].
Several MS components are present in AD and T2DM, including insulin resis-
tance, obesity, dyslipidemia, and high blood pressure [24]. These common mecha-
nisms are required to be analyzed deeper, and how each one of them contributes in 
all these pathologies should be described.
3. Amyloid forming diseases
AD and T2DM are amyloid forming diseases characterized by the presence of 
insoluble protein aggregates with a fibrillary conformation in brain and pancreas, 
respectively [39].
The presence of proteinaceous plaques that primarily comprise islet amyloid 
polypeptide (IAPP, one of the major secretory products of the pancreatic β-cells) is 
found in the majority of patients (approximately 90%) with T2DM [40]. Although 
it is not clear why normally soluble IAPP can form toxic aggregates, the evidence 
suggests that the presence of an amyloidogenic sequence in the IAPP molecule 
could increase the IAPP production/secretion from β-cells associated with elevated 
insulin demand and abnormalities in trafficking/processing of pro-IAPP contribute 
to aggregation in T2DM, causing cellular dysfunction and consequent membrane 
disruption, channel formation and toxicity [41]. Further, several groups have 
found that Aβ1–42 and IAPP forms form early intermediate assemblies as spherical 
oligomers, implicating a common folding pattern (Figure 1, [42]).
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4. Insulin alterations
In addition to T2DM (insulin resistance), T1DM (insulin deficiency) shares 
mechanisms with AD, and researchers have called the set of these characteristics 
type 3 diabetes. Defects in insulin signaling causes alterations in glucose metabo-
lism and leads to an energy imbalance causing the production of reactive oxygen 
species (ROS), DNA damage, and mitochondrial dysfunction; all these cascades 
lead to pro-apoptosis, pro-inflammatory and production of toxic peptides (tau 
and Aβ) [43].
Figure 1. 
Common ways of amyloid toxicity in Alzheimer’s disease and type 2 diabetes mellitus. Insoluble protein 
aggregates with a fibrillary conformation are present in both entities, causing cell death in neurons and β-cells 
of brain and pancreas, respectively.
Figure 2. 
Abnormal clearance of toxic species of β-amyloid by insulin degrading enzyme. Hippocampus with decreased 
levels of insulin degrading enzyme (IDE) leads to Aβ accumulation, which blocks the insulin receptor 
signaling, altering synaptic plasticity and architecture of dendritic spines.
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Insulin regulates glucose metabolism in peripheral tissues and also affects brain 
functions including cognition, memory, and synaptic plasticity through complex 
insulin/insulin receptor (IR) signaling pathways [44]. Insulin resistance in the brain 
is presented by reduced levels of insulin and insulin growth factor (IGF) receptors. 
Insulin and IGF deficiency are associated with an altered expression of insulin and IGF 
polypeptides in the brain and cerebrospinal fluid (CSF), which causes accumulation of 
Aβ [45]. On the other hand, chronic peripheral hyperinsulinemia and central insulin 
resistance can modulate tau phosphorylation, and with the loss of insulin-like growth 
factor 1 (IGF-1) signaling, an increase in tau hyperphosphorylation and NFT formation 
has been observed [46]. Through the inhibition of insulin signaling, Akt kinase is also 
inhibited, which in turn activates the glycogen synthase kinase 3β (GSK3ß), probably 
causing an increase of tau phosphorylation and altering its binding to microtubules [9].
Insulin degrading enzyme (IDE) is a major factor responsible for insulin deg-
radation. However, IDE degrades other targets like glucagon, atrial natriuretic 
peptide, and Aβ, and this could be another connection between T2DM and AD. The 
decrease of IDE in the hippocampus has been associated with a greater susceptibil-
ity of this region to the accumulation of Aβ (Figure 2, [47]).
5. Hyperglycemia
The T2DM patients have chronic hyperglycemia with an impaired glucose 
metabolism (poor glucose transport), altering neuronal cell and their metabolism 
contribute to AD. In patients with AD, a decrease in glucose metabolism has been 
observed, typically identified with fluorodeoxyglucose positron emission tomogra-
phy (PET), even before clinical symptoms of dementia were present [48].
Deficits in glucose metabolism might also potentiate the neuronal cell death 
produced by other pathological processes (such as abnormal cholesterol metabolism 
or high levels of Aβ), which in turn might be influenced by genetic predisposition 
such as possession of Apolipoprotein E ε4 (APOE ε4) alleles [49].
It is generally accepted that many DM complications are potentiated or initiated 
by the accumulation of specific forms of AGEs and their interaction with its recep-
tors (RAGE). The AGEs are molecules (including peptides and proteins) formed 
as a result of the Maillard reaction. In T2DM, periods of hyperglycemia induce an 
increase in AGEs formation, although these molecules also accumulate with aging 
accelerated formation [17, 18]. AGEs promote Aβ aggregation and cytotoxicity [19] 
and glycation of tau may enhance their aggregation as well [20].
6. Dyslipidemia
Cholesterol may be directly involved in Aβ aggregation, by abnormal oxida-
tive metabolites such as cholesterol-derived aldehydes, which can promote the 
amyloidogenesis process. Also, it was observed that APOE ε4, cholesterol, and 
Aβ are components of the amyloid plaques both in humans and animal models of 
AD. Further, low levels of cholesterol affect APP metabolism, with an increase in 
the secretion of soluble APP, a non-amyloidogenic soluble N-terminal derivative, 
also found in human CSF [50].
7. Obesity
The mechanism for the association between obesity and dementia is still far 
from being understood. Whitmer et al. alluded to the involvement of adiposity with 
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inflammation and its markers [51] while Liu et al. report that obesity also has been 
related with defective brain insulin signaling in experimental models and postmor-
tem brains [52]. This is important because there have been several reports where 
insulin regulates synaptic plasticity through altering internalization of neurotrans-
mitter receptors, in the cortex and hippocampus, which are regions of the brain 
generally associated with learning and memory, respectively [14, 53]. Therefore, 
alterations in synaptic plasticity may be associated to tau pathology, through a 
direct abnormal interaction of pathological tau species with synaptic proteins but 
also indirectly through tau-activated neuroinflammatory processes [54].
Another possible mechanism linking obesity with dementia is the oxidative 
stress, resulting from an increased intake of sugars and fats, which is the hallmark 
of the modern diet [55, 56]. Rats maintained on a diet high in refined sugar and rich 
in fat generated higher concentrations of free radicals [51]. Inflammatory processes 
promote vascular complications in obesity, T2DM, and AD. The primary regulator 
of this response is NF-κB, and in these pathologies there is an increase of the NF-κB 
family of transcription factors. In AD, the reactive astrocytes in close proximity to 
the Aβ plaques produce inflammatory cytokines, including IL-1β and TNF-α, and 
inducible iNOS, which generate free radicals such as NO, that can be neurotoxic [38].
8. Hypertension
Mice that have been chronically subjected to high blood pressure show deposi-
tion of amyloid aggregates and loss of memory when they are examined in specific 
tasks. Besides this, the hypertensive challenge increases the expression of RAGE, 
leading to Aβ deposition and learning impairment [57, 58].
A few autopsy studies have showed that the severity of AD pathology is 
increased by the presence of cerebrovascular damage, which is strongly linked to 
hypertension [58, 59].
Chronic hypertension induced vascular abnormalities in the brain, such as 
increased vascular stiffness, and decreased vessel wall plasticity; this alters arterial 
pulsations, disturbing the glymphatic system and leading to a significant increase 
of Aβ deposition in the brain parenchyma [60]. The glymphatic system is a macro-
scopic waste clearance system that utilizes a unique system of perivascular tunnels, 
formed by astroglial cells, to promote efficient elimination of soluble proteins and 
metabolites from the central nervous system [61].
Cerebral amyloid angiopathy has been shown to interact with amyloid plaques 
and NFT and to increase the severity of cognitive impairment beyond that seen in 
people with each histopathological feature separately [62].
9. Conclusion
There are several mechanisms in common between AD and T2DM, and a better 
understanding of their interrelation would contribute to upgrade the control of 
these diseases. Working in this direction will be important in order to identify new 
therapeutic or common targets, especially before the most severe symptoms of 
both pathologies occur. In addition to better management of the patients, this will 
improve the patient’s quality of life.
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